We should also be aware that albeit RVX is not a direct asset to ZENE it would come with a $600,000,000 net of research expendatures which can be used against inciome of a new owner who is in the same field of business if all was taken in a deal!,that might equate to a $2 or $300,000,000 tax saving to any interested party who wants both these companies c/w the IP and the molecules in wait. Thats what I believe would be the most plausible outcome with these epigenetic assets if we are lucky enuff. Comments  appreciated!